The Scientist

» FDA and developmental biology

Most Recent

image: Further Support for Early-Life Allergen Exposure

Further Support for Early-Life Allergen Exposure

By | September 20, 2016

Egg and peanut consumption during infancy is linked to lower risk of allergy to those foods later in life, according to a meta-analysis.

0 Comments

image: Feds Demand More Clinical Trial Reporting

Feds Demand More Clinical Trial Reporting

By | September 19, 2016

Expanded US Health and Human Services rules will require the results of more human studies to be made public.

1 Comment

image: Conditional FDA Approval for Fatal-Disease Drug

Conditional FDA Approval for Fatal-Disease Drug

By | September 19, 2016

The agency OKs Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy through its accelerated approval pathway, which requires a confirmatory clinical trial.

0 Comments

Scientists estimate the risk to fetuses exposed to the virus in utero.

0 Comments

Manufacturers have not demonstrated the safety or efficacy of 19 antibacterial agents common in hand and body soaps, according to the US Food and Drug Administration.

0 Comments

image: Theranos Withdraws Zika Blood Test

Theranos Withdraws Zika Blood Test

By | September 1, 2016

The embattled company failed to include proper safeguards, according to federal regulators.

0 Comments

image: FDA: Screen All US Blood Donations for Zika

FDA: Screen All US Blood Donations for Zika

By | August 29, 2016

The US Food and Drug Administration recommends that all blood collected across the country be tested for the virus.

0 Comments

Disrupting the light/dark cycles of pregnant mice, researchers observe detrimental effects in the mouths of the animals’ pups.

0 Comments

image: Theranos CEO Presents New Device

Theranos CEO Presents New Device

By | August 2, 2016

The troubled firm’s medical conference appearance didn’t deliver the evidence many hoped for.

0 Comments

image: NYU Halts Studies, Suspends Investigator

NYU Halts Studies, Suspends Investigator

By | June 28, 2016

Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.

2 Comments

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Human Cord Plasma Protein Boosts Cognitive Function in Older Mice
AAAS